Conference Proceedings

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, Neal D Shore, Curtis Dunshee, Lawrence Ivan Karsh, Arun Azad, Andre P Fay, Joan Carles, Beth Sullivan, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Ruben GW Quek, Akos Czibere, Karim Fizazi

Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020


TPS5598 Background: TALA blocks poly(ADP-ribose) polymerase (PARP) activity and traps PARP on single-strand DNA breaks, preventing DNA damage repair (DDR) and causing death of cells with DDR alterations (eg BRCA1/2).a TALA has been approved in multiple countries as monotherapy for germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer. ENZA is an androgen receptor (AR) inhibitor and an established therapy for mCRPC. As PARP activity has been shown to support AR function, inhibition of PARP is expected to reduce AR signaling and increase sensitivity to AR-directed therapies. In addition, AR blockade downregulates homologous recombination repair gene..

View full abstract


Funding Acknowledgements

Pfizer Inc.